Lek's Sales Revenues Soar by 52 Percent
Ljubljana, 2 February - The Ljubljana-based pharmaceuticals maker Lek upped its sales revenues by 51.9 percent to SIT 145 billion (EUR 610m) last year, subscribing importantly to the results posted by Sandoz, the generics unit of Lek's majority owner Novartis. The bulk of revenues, SIT 139bn (EUR 586m) was generated by the parent company Lek, the chairman Metod Dragonja told the press on Monday.
The rest of this news item is available to subscribers.
The news item consists of 471 characters (without spaces) or 84 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.